^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Published date:
10/02/2023
Excerpt:
Patients with NF1 mutation had longer OS in the lomustine + bevacizumab arm compared with the lomustine alone arm (P = 0.0046; FDR = 0.0276…).
Secondary therapy:
lomustine
DOI:
https://doi.org/10.1158/1078-0432.CCR-23-0926
Trial ID:
